Trials / Not Yet Recruiting
Not Yet RecruitingNCT07465666
A Real-world Study of the Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor Therapy in Hypertensive Patients in the United Arab Emirates
Real-world Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor (ARNi) Therapy in Lowering Blood Pressure in Hypertensive Patients in the United Arab Emirates
- Status
- Not Yet Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the real-world effectiveness of ARNi (sacubitril/valsartan) therapy and standard antihypertensive monotherapy in reducing blood pressure in hypertensive patients residing in the United Arab Emirates. Standard antihypertensive monotherapies will include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and calcium channel blockers (CCBs).
Conditions
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2027-04-18
- Completion
- 2027-04-18
- First posted
- 2026-03-12
- Last updated
- 2026-03-12
Source: ClinicalTrials.gov record NCT07465666. Inclusion in this directory is not an endorsement.